Table 4.

Associa tion between diure tic use at 6 months and clinical outcomes. * Reference group

Outcome	Raw Event Rate # Events/Total	Raw Event Rate # Events/Total	Unadjusted Hazard Ratio (95% CI)	P-value	Adjusted[1] (Partial Model) Hazard Ratio (95% CI)	P-value	Adjusted[2][3] (For Full Model) Hazard Ratio (95% CI)	P-value
	Continuous Use	Never on Diuretics*
All Cause Death or Hosp	633/1073 (58.99%)	158/325 (48.62%)	1.30 (1.09 – 1.54)	0.004	1.01 (0.82 – 1.24)	0.9462	0.91 (0.72 – 1.15)	0.4324
CV Death or HF Hosp	395/1364 (28.96%)	51/374 (13.64%)	2.36 (1.76 – 3.16)	<.0001	1.63 (1.17 – 2.26)	0.004	1.25 (0.87 – 1.79)	0.2240
	Initiated Diuretic Use	Never on Diuretics*
All Cause Death or Hosp	21/43 (48.8%)	158/325 (48.6%)	1.03 (0.65 – 1.62)	0.898	0.85 (0.49 – 1.46)	0.5540
CV Death or HF Hosp	12/57 (21.1%)	51/374 (13.6%)	1.56 (0.83 – 2.93)	0.166	1.42 (0.69 – 2.93)	0.3352
	Discontinued Use	Continuous Use*
All Cause Death or Hosp	31/52 (59.62%)	633/1073 (58.99%)	1.01 (0.70 – 1.44)	0.978	1.06 (0.73 – 1.55)	0.7538
CV Death or HF Hosp	17/69 (24.64%)	395/1364 (28.96%)	0.81 (0.50 – 1.32)	0.407	0.91 (0.55 – 1.50)	0.7058

^[1]All models adjusted for age, treatment arm, sex, BMI, BUN, LVEF, NYHA class and baseline loop diuretic dose.

^[2]CV Death or HF Hosp adjusted for treatment arm, LVEF, MR grade, ventricular conduction on CPX test, KCCQ symptom stability score, BUN, race, sex, age, weber class and VE/VO₂

^[3]All Cause Death or Hosp adjusted for treatment arm, Weber class, KCCQ symptom stability score, BUN, country. LVEF, sex, beta blocker dosage, MR grade, ventricular conduction on CPX test